Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality

Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412-414. doi: 10.1093/ehjcvp/pvaa056.

Francesco Cannata^{1

2}, Mauro Chiarito^{1

2}, Bernhard Reimers^{1

2}, Elena Azzolini^{1

2}, Giuseppe Ferrante^{1

2}, Ilaria My^{1

2}, Giacomo Viggiani^{1

2}, Cristina Panico^{1

2}, Damiano Regazzoli^{1

2}, Michele Ciccarelli^{1

2}, Antonio Voza^{1

2}, Alessio Aghemo^{1

2}, Hongliang Li³, Yibin Wang⁴, Gianluigi Condorelli^{1

2}, Giulio G Stefanini^{1

2}

¹ Humanitas Clinical and Research Hospital IRCCS, Rozzano-Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.
³ Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
⁴ Department of Anesthesiology, Cardiovascular Research Laboratories, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

No abstract available

Publication types